Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 10/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 9/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4350314 | 0.84 | CYP2A6 (0.68) | CYP3A4CYP2C9CYP2B6CYP2E1CYP2A6 | |
| SCHEMBL6067952 | 0.80 | CYP2A6 (0.50) | CYP3A4CYP2C9CYP2B6CYP2E1CYP2A6 | |
| SCHEMBL3997707 | 0.79 | — | — | |
| SCHEMBL29551999 | 0.79 | HSD17B1 (0.88) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL69369 | 0.79 | HSD17B1 (0.88) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL28164029 | 0.78 | CYP2A6 (0.82) | CYP3A4CYP2C9CYP2B6CYP2E1CYP2A6 | |
| SCHEMBL8050006 | 0.77 | HSD17B1 (0.94) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2B6 | |
| Ammonia Solution, Strong SCHEMBL28150307 | 0.77 | HSD17B1 (0.83) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL13210803 | 0.76 | ESR1 (0.61) | HSD17B1HSD17B2CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL17004981 | 0.76 | CYP2A6 (0.70) | CYP3A4CYP2C9CYP2B6CYP2E1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-1838304-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORP (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GILLESPIE PAUL | 2009-06-18 | — | — | US | disclosed |
| US-7524870-B2 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2009-04-28 | — | — | US | disclosed |
| CN-101068803-A | Biaryloxymethylarene carboxylic acid compounds | HOFFMANN LA ROCHE (CH) | 2007-11-07 | — | — | CN | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
| US-5444084-A | Anticholesterol, antilipidemic agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-22 | — | — | US | disclosed |
| US-5439932-A | Anticholesterol agents | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-08 | — | — | US | disclosed |
| EP-0609448-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVE HAVING SQUALENE EPOXIDASE INHIBITORY EFFECT AND USE THEREOF | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-08-10 | — | — | EP | disclosed |
| US-5306728-A | Substituted amine derivatives having antihyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0448078-A2 | Substituted amine derivatives having anti-hyperlipemia activity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-4212882-A | ANTIINFLAMMATORY INTERMEDIATES | RIKER LABORATORIES, INC. (US) | 1980-07-15 | — | — | US | disclosed |
| US-4172082-A | ANTIINFLAMMATORY AGENTS | RIKER LABORATORIES, INC. (US) | 1979-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156635-A1 | BIARYLOXYMETHYLARENECARBOXYLIC ACIDS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, GSK3A | HSD17B1 19/4885HSD17B2 18/4885CYP3A4 284/4885 |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | HSD17B1 19/4885HSD17B2 18/4885CYP3A4 284/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | HSD17B1 2694/4885HSD17B2 2476/4885CYP3A4 494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.